📇 Rhumatologue · PARIS · (75) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
16 articles scientifiques publiés — formation continue solide
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR ELISABETH RIVAUD
22 RUE DES BELLES FEUILLES, 75116 PARIS
HOPITAL FOCH
40 R WORTH BP 36, 92151 SURESNES CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The European respiratory journal · 2015
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by failure of superoxide production in phagocytic cells. The disease is characterised by recurrent infections and inflammatory events, frequently affecting the lungs. Improvement of life expectancy now allows most patients to reach adulthood. We aimed to describe the pattern of pulmonary manifestations occurring during adulthood in CGD patients. This was a retrospective study of the French national cohort of adult patients (≥16 years old) with CGD. Medical data were obtained for 67 adult patients. Pulmonary manifestations affected two-thirds of adult patients. Their incidence was significantly higher than in childhood (mean annual rate 0.22 versus 0.07, p=0.01). Infectious risk persisted despite anti-infectious prophylaxis. Invasive fungal infections were frequent (0.11 per year per patient) and asymptomatic in 37% of the cases. They often required lung biopsy for diagnosis (10 out of 30). Noninfectious respiratory events concerned 28% of adult patients, frequently associated with a concomitant fungal infection (40%). They were more frequent in patients with the X-linked form of CGD. Immune-modulator therapies were required in most cases (70%). Respiratory manifestations are major complications of CGD in adulthood. Noninfectious pulmonary manifestations are as deleterious as infectious pneumonia. A specific respiratory monitoring is necessary.
Respiratory research · 2019
Abstract Background Bronchiectasis is a heterogeneous disease depending on etiology. It represents the most frequent non-infectious pulmonary complication of primary immunodeficiencies (PID). We investigated whether bronchiectasis associated with PID had a distinct course in comparison to bronchiectasis of other causes. Methods Retrospective single-center study of adult patients diagnosed with non-cystic fibrosis bronchiectasis with more than 5 years of follow-up and at least 4 pulmonary functional tests available at one year apart. They were divided into three groups: PID- related bronchiectasis, idiopathic/post infectious-related bronchiectasis and other causes of bronchiectasis. Respiratory functional data and clinical outcomes were compared. Results Of 329 patients with bronchiectasis diagnosed in Foch Hospital (Suresnes, France), 98 patients fulfilled the selected criteria (20 PID-related cases, 39 idiopathic or post-infectious cases, and 39 cases with other causes). Median time of follow-up was 9.5 years. Groups were similar concerning initial characteristics (female 70.4%, never smokers 59.2%, mild severity bronchiectasis according to the FACED score and median FEV1 at diagnosis 73.5% predicted values [Q1–Q3: 53.75–90.5]), except PID patients who were younger (median age of 51.5 vs 62 years, p = 0.02). Eighty-five percent of PID patients received immunoglobulin substitution (median trough level was measured at 10.5 g/dl [10;10.92]). Global median FEV1 annual decline was 25.03 ml/year [8.16;43.9] and 19.82 ml/year [16.08;48.02] in the PID patients group. Forty-five percent of patients had bacterial colonization, pneumoniae occurred in 56% of patients and median exacerbation annual rate was 0.8 [0.3–1.4]. Hemoptysis occurred in 31.6% of patients. Global mortality rate was 11.2%. We did not record any significant difference for all clinical and functional outcomes between patients with PID and other etiologies. The median decline in FEV1 was similar in the three groups. Conclusions The course of PID-related bronchiectasis was similar to bronchiectasis of other causes. Provided that patients receive immunoglobulin replacement, the course of PID-related bronchiectasis seems to be independent of the underlying immune disorder.
Journal of thoracic imaging · 2007
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Respiratory medicine and research · 2024 · Case Reports
Couderc LJ, Fleury-Feith J, Longchampt E, Wagner I, et al.
Respiratory research · 2019 · Comparative Study
Goussault H, Salvator H, Catherinot E, Chabi ML, et al.
The European respiratory journal · 2018 · Letter
Loiseau C, Lemonnier F, Randrianarivelo O, Itzykson R, et al.
Lung cancer (Amsterdam, Netherlands) · 2018 · Case Reports
Chabrol A, Mayenga M, Hamid AM, Friard S, et al.
The European respiratory journal · 2018 · Case Reports
Salvator H, Berti E, Catherinot E, Rivaud E, et al.
Leukemia & lymphoma · 2018 · Case Reports
Sesé L, Rivaud E, Bron C, Leblond V, et al.
Journal of clinical immunology · 2017 · Case Reports
Colin de Verdière S, Noel E, Lozano C, Catherinot E, et al.
The European respiratory journal · 2016 · Letter
Catherinot E, Longchampt E, Ferroni A, Rivaud E, et al.
The European respiratory journal · 2015 · Case Reports
Lhote R, Theodore C, Issoufaly T, Francois D, et al.
The European respiratory journal · 2015 · Journal Article
Salvator H, Mahlaoui N, Catherinot E, Rivaud E, et al.
American journal of respiratory and critical care medicine · 2014 · Case Reports
Didier M, Guedin P, Staub F, Catherinot E, et al.
BMC infectious diseases · 2011 · Case Reports
Rammaert B, Couderc LJ, Rivaud E, Honderlick P, et al.
Revue de pneumologie clinique · 2011 · Journal Article
Toper C, Rivaud E, Daniel C, Cerf C, et al.
Journal of thoracic imaging · 2007 · Journal Article
Guihot A, Couderc LJ, Rivaud E, Galicier L, et al.
Transplantation · 2007 · Journal Article
Guihot A, Becquemin MH, Couderc LJ, Randrianarivelo O, et al.
Lancet (London, England) · 2002 · Case Reports
Catherinot E, Rivaud E, Epardeau B, Cahen P, et al.